DDInter1570 DDInter1925
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Ranolazine {u} (Compound) upregulates {v} (Gene) DENND2D
DENND2D {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Vemurafenib
Ranolazine {u} (Compound) downregulates {v} (Gene) TPI1
TPI1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Ranolazine {u} (Compound) causes {v} (Side Effect) Eosinophilia
Eosinophilia {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Ranolazine {u} (Compound) upregulates {v} (Gene) DENND2D
DENND2D {u} (Gene) is regulated by {v} (Gene) SYNE2
SYNE2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Ranolazine {u} (Compound) downregulates {v} (Gene) TPI1
TPI1 {u} (Gene) is regulated by {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vemurafenib
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Ranolazine (Compound) upregulates DENND2D (Gene) and DENND2D (Gene) is upregulated by Vemurafenib (Compound)
Ranolazine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Vemurafenib (Compound)
Ranolazine (Compound) downregulates TPI1 (Gene) and TPI1 (Gene) is downregulated by Vemurafenib (Compound)
Ranolazine (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Ranolazine (Compound) upregulates DENND2D (Gene) and DENND2D (Gene) is regulated by SYNE2 (Gene) and SYNE2 (Gene) is upregulated by Vemurafenib (Compound)
Ranolazine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Ticagrelor (Compound) and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Ranolazine (Compound) downregulates TPI1 (Gene) and TPI1 (Gene) is regulated by ALB (Gene) and ALB (Gene) is bound by Vemurafenib (Compound)